PRESS RELEASE
Cevidra SAS and AFYX Therapeutics A/S announce distribution and collaboration agreement for France.
Hørsholm, Denmark January 13th 2025 –
AFYX Therapeutics A/S and Cevidra SAS are pleased to announce a strategic partnership aimed at bringing innovative treatments for Head and Neck Cancer to the French market.
Under this collaboration, Cevidra will serve as the local pharmaceutical Exploitant and distribution partner in France, leveraging its expertise to support AFYX in the introduction of new therapies to healthcare professionals.
About Cevidra and AFYX
Cevidra, with its Exploitant status, is the gateway to the French market for pharmaceutical companies seeking to commercialize medicines through Early Access Programs (AAC, AAP) or Licensed Products (MA). As a one-stop company, Cevidra offers fully integrated solutions, including price and reimbursement, local pharmacovigilance, CRO services for data collection, distribution, and tailored promotional activities.
AFYX – Reversed Innovation is our core value.
As a leader in the biopharmaceutical industry, reversed innovation aligns with the broader theme, as we take an existing product or technology and use it to address a new or previously overlooked or unconsidered medical problem or condition.
For more information: https://afyxtx.com
For more information please contact:
Helle Heidensleben;
hh@afyxtx.com; +453162 7798
Loïc Fiévet ;
l.fievet@cevidra.com; +33493705831
Claus Møller-San Pedro
CEO & Founder